Alvotech Announces Positive Top-Line Results from a …
WEBJan 29, 2024 — Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Hepagene Therapeutics, Inc, Announces Dosing of First Healthy …
WEBSHANGHAI, China I October 16, 2019 I Hepagene Therapeutics, Inc, a clinical stage drug discovery and development company which devotes its efforts towards discovering, developing and delivering innovative medicines that help patients prevail over liver diseases, announced today that it has dosed the first healthy volunteer in a phase I clinical trial of HPG1860 in the United States.
Novo Nordisk acquires Embark Biotech, including its lead asset ...
WEBSep 1, 2023 — COPENHAGEN, Denmark I August 30, 2023 I Embark Laboratories announced today that Novo Nordisk has acquired Embark Biotech, including its lead metabolic program, and has entered a three-year research and development collaboration to discover and develop novel pharmaceuticals to treat obesity and related co-morbidities.. Under the acquisition agreement for Embark Biotech, Novo Nordisk receives ...
Hanmi Enters into Clinical Trial Collaboration and Supply …
WEBApr 23, 2024 — Hanmi Pharmaceutical announces Clinical Trial Collaboration with MSD to evaluate ‘BH3120’ in combination with KEYTRUDA in phase 1 clinical trial in patients with progressive or metastatic solid tumors
Biosion Announces Phase II Study Start for Anti-TSLP mAb BSI …
WEBAug 1, 2023 — NEWARK, NJ, USA and NANJING, China I July 31, 2023 I Biosion USA, Inc. (Biosion), a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis (AD) . “We are pleased to have initiated this important Phase 2 trial, which brings us closer to delivering a new treatment ...
Harbour BioMed Reports Positive Topline Results from
WEBJul 6, 2021 — Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Small Molecules - Pipelinereview
WEB10 September 2024. Clear Scientific Reports Positive Topline Phase 1 Clinical Trial Data for CS-1103, a Potential First-in-Class Therapeutic for Meth and Fentanyl Overdose. 10 September 2024. New results from the Investigational agent BAY 2927088 in HER2-mutant non-small cell lung cancer (NSCLC) presented at WCLC. 9 September 2024.
Catalent Partners with Spicona to Develop COVID-19
WEBJun 11, 2020 — NEW YORK, NY and SOMERSET, NJ, USA I June 10, 2020 I Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed an agreement with Spicona, Inc. to develop a virus-like protein (VLP)-based vaccine against COVID-19.
Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN …
WEBMar 2, 2021 — Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and ...
WEBJan 10, 2022 — Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.